SARS-CoV-2 - Duvelisib - Therapeutic Candidates

SARS-CoV-2 - Duvelisib - Therapeutic Candidates


Duvelisib, whose commercial name is Copiktra, is a molecule that inhibits the delta and gamma isoforms of the PI3 Kinase (PI3K for phosphoinositide-3 kinase). Duvelisib has potential immunomodulatory and antineoplastic activities. Duvelisib inhibits activation of PI3K delta/gamma-mediated signalling pathways, which may result in reduced cell proliferation in tumour cells expressing PI3K delta/gamma. Unlike other PI3K isoforms, delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal non-neoplastic cells is little or not affected, resulting in a more favourable side effect profile. Duvelisib is used in the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
The excessively high mortality rates of severe and critical cases of COVID-19 warrant the identification and evaluation of new therapies that could potentially mitigate the advanced manifestations of the disease. Based on preclinical data, the researchers hypothesize that inhibition of PI3K by duvelisib could potentially suppress aberrant overactivation of the innate immune system, preferentially polarize macrophages, reduce lung inflammation and limit viral persistence, thereby improving patient outcomes.

Cat#
Description
Size
Price Excl. VAT
HY-17044A-100mg
 100mg 
HY-17044A-10mg
 10mg 
HY-17044A-1mL
 10mM/1mL 
HY-17044A-50mg
 50mg 
HY-17044A-5mg
 5mg 
HY-17044-S
 0,5-1mg 
HY-17044-5mg
 5mg 
HY-17044-50mg
 50mg 
HY-17044-1mL
 10mM/1mL 
HY-17044A-S
 0,5-1mg 
HY-17044-10mg
 10mg 
HY-17044-100mg
 100mg 
10-4788-25mg
 25 mg 
10-4788-5mg
 5 mg 
abx184681-5mg
 5mg 
A12422-10mM-D
 10mM*1mLinDMSO 
abx182436-1g
 1g 
abx182436-5g
 5g 
MBS575674-1ml
 1ml/10mM (In DMSO) 
MBS575674-10mg
 10 mg 
MBS575674-50mg
 50 mg